Welcome to our dedicated page for Quest Diagnostics news (Ticker: $DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.
Quest Diagnostics received high praise from a patient at their Voorhees PSC location in New Jersey, highlighting exceptional staff service and professionalism. The team's dedication and consistent excellent service reflect the company's core values. The positive feedback showcases a strong commitment to customer care and satisfaction.
Quest Diagnostics, a leading diagnostic information services company, will have its CEO speak at the 2024 Leerink Partners Healthcare Crossroads Conference. The event will cover the company's strategy, performance, and market trends, with a live webcast available for investors.
Quest Diagnostics and PathAI announced a collaboration to accelerate the adoption of digital and AI pathology innovations to improve cancer diagnosis. Quest will acquire select assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction is expected to be completed in the second quarter of 2024. Additionally, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the U.S.
Quest Diagnostics has appointed Murali Balakumar as the Senior Vice President and Chief Information and Digital Officer, bringing 25 years of experience in technology strategy across healthcare, financial services, and transportation industries. As a digital transformation leader, Mr. Balakumar will oversee information technology, data informatics, and digital solutions for the company.
Quest Diagnostics collaborated with St. James Health to offer no-cost Blueprint for Wellness screenings during a Choose Healthy Life event at the Metropolitan Baptist Church in Newark. The event celebrated the expansion of the Willing Heart Community Care Center, supported by the Quest Diagnostics Foundation. The initiative aims to address social inequities in healthcare, employment, housing, and poverty. Quest provided 51 attendees with Blueprint for Wellness screenings, showcasing their commitment to health equity in underserved communities.
Quest Diagnostics and PathAI announced a collaboration to accelerate AI and digital pathology adoption in cancer diagnosis. Quest will acquire certain assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction includes licensing agreements and is expected to close in Q2 2024. The partnership aims to improve cancer care quality and efficiency with cutting-edge technologies.
The Quest Diagnostics Foundation and Green Bronx Machine have expanded their collaboration to bring indoor gardening curriculum to more communities. The foundation grant will help extend the reach of Green Bronx Machine's school-based model to 50 schools in Baltimore and Houston, highlighting the importance of nutrition education for health equity. The initiative is part of the Quest for Health Equity (Q4HE) program, supporting under-resourced schools and communities.